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Abstract
Introduction: The pathological course of several chronic inflammatory diseases, including cystic fibrosis, chronic
obstructive pulmonary disease, and rheumatoid arthritis, features an aberrant innate immune response dominated
by neutrophils. In cystic fibrosis, neutrophil burden and activity of neutrophil elastase in the extracellular fluid have
been identified as strong predictors of lung disease severity.
Review: Although neutrophils are generally considered to be rigid, pre-programmed effector leukocytes, recent
studies suggest extensive plasticity in how neutrophil functions unfold upon recruitment to peripheral tissues, and
how they choose their ultimate fate. Indeed, upon migration to cystic fibrosis airways, neutrophils display dysregulated
lifespan, metabolic activation, and altered effector and regulatory functions, consistent with profound adaptation and
phenotypic reprogramming. Licensed by signals present in cystic fibrosis airway microenvironment to survive and
develop these novel functions, neutrophils orchestrate, in partnership with the epithelium and with the resident
microbiota, the evolution of a pathological microenvironment. This microenvironment is defined by altered proteolytic,
redox, and metabolic balance and the presence of stable luminal structures in which neutrophils and microbes coexist.
Conclusions: The elucidation of molecular mechanisms driving neutrophil plasticity in vivo will open new treatment
opportunities designed to modulate, rather than block, the crucial adaptive functions fulfilled by neutrophils.
This review aims to outline emerging mechanisms of neutrophil plasticity and their participation in the building
of pathological microenvironments in the context of cystic fibrosis and other diseases with similar features.
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Introduction
Neutrophils constitute the first line of defense against
infection in most organisms. It is estimated that the hu-
man body produces 109 neutrophils/kg/day, making
them the most abundant leukocytes in bone marrow
(BM) and blood. Neutrophils play an important role in
protective immunity, which explains the severe patholo-
gies arising upon hereditary or acquired impairment of
neutrophil number and function. Blood neutrophils are
conventionally thought of as terminally differentiated cells
with little license to adapt to conditions within tissues be-
yond their ability to kill pathogens intracellularly by
phagocytosis, or extracellularly by degranulation or release
of DNA-based neutrophil extracellular traps (or NETs) in
a recently discovered process dubbed “NETosis”.
However, in the context of cystic fibrosis (CF) lung
disease, neutrophils show complex properties, detailed
below, that come in stark contrast with the rigid pre-
programmed phenotype generally expected of them and
instead emphasize their inherent plasticity. CF is a her-
editary, recessive disease that predominately impacts in-
dividuals of European ancestry. According to the World
Health Organization, its incidence varies between 1 in
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2000 and 1 in 3500 newborns worldwide. The gene mutated
in CF patients encodes the CF transmembrane conductance
regulator (CFTR), an ATP-binding cassette family member
that regulates the movement of anions, such as chloride, bi-
carbonate, thiocyanate, and glutathione (GSH), across the
plasma membrane [1, 2]. So far, more than 1800 disease-
causing mutations have been identified among CF patients,
with the F508Del mutation being the most frequent (~70%
of mutated alleles) [3, 4]. Digestive enzyme supplements
have noticeably increased CF patients’ lifespan and shifted
the main cause of morbidity from nutrient malabsorption
due to pancreatic failure to chronic lung disease [5].
Impaired mucociliary clearance, bacterial infection,
and neutrophilic inflammation are all hallmarks of CF
lung disease [6, 7]. Among those, neutrophil burden and
extracellular activity of the protease neutrophil elastase
(NE) in CF airway fluid correlate best with disease pro-
gression in CF patients, from infancy to adulthood [8].
The role of neutrophil inflammation in CF pathophysi-
ology has been exhaustively reviewed elsewhere [9–11].
Recent reviews detail the putative role of other immune
cells, such as macrophages, in CF lung disease [12–14].
In the present review, our goal is to direct the attention
of the reader to the phenotypic reprogramming process
that neutrophils undergo in the context of CF lung dis-
ease, and explore potential mechanisms and treatment
opportunities afforded by this newly discovered process.
Importantly, this new view of neutrophils, which we
illustrate in the context of CF, echoes recent findings
made in the context of acute infection and sepsis, as well
as other chronic inflammatory diseases such as chronic
obstructive pulmonary disease (COPD), rheumatoid
arthritis (RA), and systemic lupus erythematosus, as well
as cancer, where neutrophils also display new, complex
phenotypes and effector functions [15].
Review
Neutrophil plasticity in CF lung disease: emergent
mechanisms
Lifespan and aging
Pulse-chase experiments were conducted recently to
measure the lifespan of human neutrophils in blood.
Models accounting for the loss of the deuterium label
led to estimates of a few hours to up to 5 days [16, 17].
Although their exact lifespan is debated, it is of general
consensus that neutrophils leave the BM with a default
pro-apoptotic program that can be inhibited by stimuli
received upon migration to peripheral tissues [18, 19]. In
CF, there is no experimental data on the precise lifespan
of neutrophils in the lung, and this subject remains de-
bated. On the one hand, the hostile environment of the
CF lung, and notably the presence of bacterial toxins,
could induce rapid necrosis of incoming neutrophils
[20–22]. On the other hand, neutrophil lifespan may be
extended by several factors, such as pro-survival signals
from neutrophils, as well as exogenous drugs, and epi-
thelial and microbial inflammatory mediators and me-
tabolites. For example, Sutanto et al. [23] showed that
primary epithelial cells from CF infants not only secrete
higher levels of inflammatory mediators compared to
their healthy counterparts at baseline but also display an
increased production of interleukin-8 (IL-8) in response
to human rhinovirus infection. In addition to being a
strong chemoattractant [24], IL-8 can delay neutrophil
apoptosis [25]. Thus, the CF airway epithelium may
contribute to a higher lifespan of neutrophils recruited
to the lumen.
To achieve a balanced number of neutrophils in blood,
the high daily rate of release of mature young neutro-
phils into the bloodstream is compensated by the clear-
ance of senescent neutrophils from it. Circadian rhythm
is a major factor influencing hematopoiesis in general
and neutrophil turnover in particular [26–28]. From a
phenotypic standpoint, developing neutrophils in the
bone marrow (BM) express the chemokine receptor
CXCR4, which acts as a retention signal by binding to its
cognate ligand CXCL12 on stromal cells. The release of
mature neutrophils into the circulation coincides with the
downregulation of CXCR4 expression, and concomitant
increase in expression of CXCR2, a receptor for IL-8.
However, senescent neutrophils increase CXCR4 expres-
sion again [17], which is thought to lead to their return to
the BM where they are cleared by resident macrophages.
In addition to its role in mediating cell retention in the
BM, CXCR4 signaling has been proposed as a direct regu-
lator of neutrophil lifespan. In mice, CXCR4 expression is
increased in neutrophils after migration to the lungs and
correlates with increased lifespan [29]. In patients with
COPD, neutrophils are present in large numbers within
the bronchoalveolar lavage fluid (BALF) [30] and express
higher levels of CXCR4 compared to control subjects [31].
Similarly, neutrophils isolated from the sputum of CF pa-
tients showed increased surface expression of CXCR4
compared to blood neutrophils [32], and its ligand
CXCL12 was detected in some CF sputum samples, sug-
gesting a potential role of this pathway within the CF
airway lumen.
In addition to the CXCR4/CXCL12 axis, new insights
from the zebrafish model of neutrophil development
show that signaling through the oxygen-dependent tran-
scription factor hypoxia-inducible factor-1α (HIF-1α)
can also significantly delay neutrophil apoptosis [33].
Since affected areas in CF lungs become highly hypoxic
due to mucus impaction and fast oxygen consumption
by activated neutrophils [34], it is tempting to speculate
that HIF-1α signaling may be triggered in neutrophils
present in this pathological microenvironment, affecting
their lifespan. Consistent with this notion, significant
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HIF-1α signaling has been demonstrated in the βENaC
mouse model of CF lung disease, inducing substantial
pro-inflammatory signaling within the epithelium that
results in neutrophilic inflammation [35].
Interestingly, it has been suggested that neutrophils in
CF patients have an intrinsic increase in lifespan due to
the mutation of the CFTR gene. Indeed, ex vivo experi-
ments on blood neutrophils isolated from healthy con-
trols and CF patients with the F508Del mutation showed
delayed apoptosis in the latter [36, 37]. However, these
data do not imply increased lifespan in vivo. Also, since
ongoing treatments can significantly impact neutrophil
behavior [38], it is likely that drugs administered to CF
patients from whom neutrophils are collected can alter
the lifespan of these cells ex vivo. Another interesting
factor to consider when reflecting on potential influ-
ences exerted onto neutrophil lifespan is that of the resi-
dent microorganisms. Indeed, it has been demonstrated
that neutrophil biogenesis and aging in mice is con-
trolled, in part, by the gut microbiome [39, 40]. In pa-
tients with chronic infections, e.g., CF or COPD, it is
likely that the lung microbiome could also play a role in
shaping neutrophil lifespan [41], although this notion re-
mains controversial [42, 43].
In the context of a normal immune response to an in-
sult, increased neutrophil lifespan can be beneficial for
the host, at least temporarily. However, if this response
becomes dysregulated, it can constitute a double-edged
sword [44]. To this day, many questions relative to the
recruitment of neutrophils and their precise lifespan
within the CF lung in vivo remain unanswered. A key
difficulty resides in studying these mechanisms in vivo,
and in untangling factors intrinsic to CF (compared to
other diseases with similar neutrophilic inflammation,
such as COPD), and those affected by exogenous drugs.
Finally, since neutrophils, the airway epithelium, and mi-
croorganisms all contribute to CF lung disease, integra-
tive approaches combining signals from all components
of this pathological microenvironment are needed to
yield better understanding of the mechanisms at play.
Overview of effector functions
In the course of inflammation, neutrophils recruited
from blood cross into tissues and organize themselves in
“swarms” to travel to the site of injury. Neutrophil mi-
gration responds to gradients of exogenous and auto-
crine/paracrine chemokines (e.g., IL-8), cytokines (e.g.,
tumor necrosis factor α), as well as bioactive lipids (e.g.,
leukotriene B4 (LTB4)) [45, 46]. Dynamic expression of
specific receptors to these chemokines, cytokines, and
bioactive lipids is critical to neutrophil migration. In
addition, neutrophils express a plethora of pattern rec-
ognition receptors (PRRs) that allow them to sense and
capture signals present in their surroundings in the form
of pathogen-associated molecular patterns (PAMPs) or
danger-associated molecular patterns (DAMPs) [47].
PAMPs (e.g., lipopolysaccharide from gram-negative
bacteria) and DAMPs (e.g., extracellular advanced glyca-
tion endproducts or adenosine triphosphate) are present
in damaged tissues and play a major role in influencing
the functional fate of incoming neutrophils, notably the
mobilization of intracellular granules.
Neutrophil granules are designated based on their con-
tent and order of production during BM development.
Primary or azurophilic granules are formed at the early
stages of neutrophil lineage formation in the BM (myelo-
blast to promyelocyte) and contain the potent proteases
neutrophil elastase (NE) and cathepsin G, the chlorinating
enzyme myeloperoxidase (MPO), and defensins. Second-
ary or specific granules arise at the later metamyelocyte
stage and are characterized by the presence of lactoferrin,
collagenase, carcinoembryonic antigen cell adhesion mol-
ecule family members CD66a and CD66b, and the anti-
protease cystatin C. Tertiary or gelatinase granules appear
at the band cell stage, right before the final segmented
stage of neutrophil BM development, and enclose
lysozyme and matrix metalloproteinase 9 (MMP9).
Secretory vesicles are present only in mature neutrophils
and are thought to be produced by endocytosis of surface
expressed proteins, enabling their rapid redeployment at
the surface upon activation, as exemplified by the upregu-
lation of PRR surface expression upon priming in blood
[48, 49]. Mobilization of secretory vesicles followed by ter-
tiary and secondary granules appears to be a default acti-
vation path for neutrophils. By contrast, primary granules
generally fuse either with the phagosome or the nucleus
[50], the latter being part of the recently discovered
NETotic fate of neutrophils. During NETosis, DNA is
decondensed, released along with histones, and com-
plexed with cationic primary granule proteins (chiefly NE
and MPO), thus forming extracellular traps endowed with
antimicrobial activities [51].
Until recently, it was believed that, due to the high
self-harming potential of primary granule enzymes, the
content of primary granules was rarely if ever dis-
charged actively in the extracellular environment dur-
ing the normal course of an inflammatory response.
Thus, the massive amounts of NE and MPO present in
the pathological milieu of CF and COPD airway fluid
were thought to stem from the passive release of pri-
mary granules following neutrophil necrosis. However,
the discovery of viable neutrophils in the CF lung
lumen capable of active primary granule exocytosis has
overturned this belief [52]. In these cells, mobilization
of primary granules to the plasma membrane is not a
passive outcome, but rather a finely orchestrated mech-
anism leading to a fate distinct from phagocytosis and
NETosis (Fig. 1). The molecular mechanisms behind
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the differential primary granule mobilization to the phago-
some (phagocytosis), nucleus (NETosis), or plasma mem-
brane (third, and presumably distinct, fate), and whether
each of the three described fates is exclusive of the others,
are but a few examples of the current mysteries surround-
ing neutrophil biology that will have to be addressed in
future research.
Focus on neutrophil elastase
A major effector of neutrophils with a critical role in CF
is neutrophil elastase (NE), a serine protease composed
of 218 amino acids. First discovered in 1968 by Janoff
and Scherer [53] in the granular fraction of neutrophils,
it took 15 more years for the sequence of NE to become
known [54]. Upon primary granule release, the majority
of NE remains bound to the plasma membrane [55, 56],
which enables it to have its catalytic region facing the
extracellular environment while concealing its regulatory
region, thus making inhibitors less effective. The import-
ant pathophysiological role played by NE is highlighted
by the fact that NE-knockout mice are highly susceptible
to sepsis induced by gram-negative bacteria [57]. In
humans, cyclic neutropenia, a genetic disease caused by
mutations in the NE-coding ela2 gene, is associated with
recurrent troughs in neutrophil production and height-
ened susceptibility to infections, suggesting a dual devel-
opmental and functional role for NE [58, 59].
In CF, increased presence of active NE in the airway
fluid of pediatric and adult patients has been correlated
with impaired structural integrity, worsening lung func-
tion, and decreased body mass index over time [60–63].
In a recent study, detectable NE activity in BALF of 3-
month-old CF infants was the best predictor of future
bronchiectasis development, with a likelihood seven
times higher at 12 months and four times higher at the
age of three than 3-month-old CF infants with no de-
tectable NE in BALF activity [62]. Since BALF is highly
diluted, due the way it is collected, it is possible that de-
tection of free NE activity in CF infants happens only
after constant NE release has overcome the secreted
antiprotease shield present in the airways, thereby cross-
ing a certain pathological threshold. Thus, more sensi-
tive methods for extracellular NE detection are required
in order to detect abnormal neutrophilic inflammation
before it reaches a critical level and causes significant
pathology.
Complementing early work by Owen and colleagues
demonstrating NE activity in close vicinity to the plasma
membrane of exocytosing neutrophils [55], additional
work needs to be performed to determine the exact
localization of NE in the extracellular environment within
CF and COPD airways in vivo. Recently, Schulenburg et
al. [64] designed a Förster resonance energy transfer probe
specific for NE activity that could serve such a purpose.
Potential applications of such probes have been
Fig. 1 Primary granule mobilization and functional fates of human neutrophils. Recent studies have revealed the existence of multiple functional
fates of neutrophils, which lead to different interactions with incoming bacteria (in red). Fusion of primary granules (in blue) to the phagosome
drives neutrophils toward the classical phagocytic fate (1), while their mobilization to the nucleus drives them toward the extrusion of DNA-based
extracellular traps in a process called “NETosis” (2). By contrast, primary granule fusion with the plasma membrane instead leads to hyperexocytosis
and potential reprogramming (3), a third fate that further emphasizes the functional plasticity of human neutrophils
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extensively reviewed elsewhere [65]. Due to the wide
range of proteins with NE cleavage sites that could poten-
tially serve as NE substrates within pathological environ-
ments (see Table 1), it is hard to predict which of these
proteins will be effectively proteolyzed in vivo. Among
these proteins, one finds both immunological and non-
immunological target proteins expressed by neutrophils, T
cells, macrophages, and epithelial cells. Further adding to
this complex picture, NE can be acquired by neighboring
cells following its release by neutrophils [66]. This effect-
ively extends the number of possible targets of NE-
mediated cleavage to include intracellular proteins, which
in turn affect signaling in neighboring cells (Table 2).
A prototypical example highlighting the impact of un-
opposed NE activity in a pathological milieu is its ability
to activate MMP9, another potent neutrophil protease.
Upon concomitant release of primary and tertiary gran-
ules, NE can potentiate MMP9 through direct activatory
cleavage and/or indirect degradative cleavage of its in-
hibitor tissue inhibitor of metalloprotease-1 (TIMP-1),
leading to increased collagen degradation, tissue damage,
and bronchiectasis in CF children [67, 68]. Likewise, sur-
face phagocytic receptors CD14 and CD16 on neutro-
phils found in the lumen of CF patients’ lungs are
inactivated by NE in autocrine and paracrine fashion
[69]. Moreover, antibody-mediated bacterial killing is im-
paired not only on the receptor side but also on the
opsonization potential of the antibody. As matter of fact,
it has been shown that NE can cleave immunoglobulins
A (IgA) [70] and G (IgG) [71, 72] near their hinge re-
gion. This leads to the formation of Fab and Fc frag-
ments that are able to bind separately to the bacteria
and receptors on target cells, thus losing the adaptor
function of the antibody [73, 74]. In addition to NE, the
CF opportunistic pathogen Pseudomonas aeruginosa also
contributes its own elastase activity, which can also
cleave IgG [75]. This dual inhibition exerted by NE on
antibodies present in the CF airway lumen has implica-
tions for the design of vaccine strategies aiming to in-
duce anti-bacterial responses in CF, suggesting that
these may be severely limited by the high extracellular
NE burden. Another example of effector function modu-
lation by NE is the cleavage of the IL-8 receptor CXCR1,
associated with impaired bacterial killing [76]. This may
contribute to the infection by opportunistic bacteria such
as Staphylococcus aureus and P. aeruginosa, which are
also hallmarks of CF lung disease [77, 78]. Whether NE-
mediated damage is a primary cause of these persistent
infections or whether other elements in the CF lung envir-
onment also contribute to impaired clearance of these
specific bacteria remains a matter of debate [79, 80].
Beyond the failed clearance of these bacteria, their
continued adaptation to the CF environment, notably
their switch to mucoid and biofilm resistance pheno-
types, may also benefit from NE activity. Indeed, NE-
mediated activity can repress flagellin transcription in
Table 1 Direct targets of NE-dependent regulation
Immunological targets
Activated by cleavage Inhibited by cleavage
Arginase-1 [106] CD2/CD4/CD8 [107]
Chemerin [161] CD14 [162]
IL-36 receptor antagonist [163] CD16 [164]
IL-8 [84] CD43 [165]
MMP-9 [67] CCL3 [166]
PAR-1/PAR-2 [167, 168] Complement factors [169–172]












Activated by cleavage Inhibited by cleavage
α2β3 integrins [182] Cadherins [183]
EGFR [184] Elastin [185]
ENaC [186, 187] Ferritin [188]
Fibrin stabilizing factor XIII [189]
Surfactant protein A [190]
Surfactant protein D [191]
Vascular endothelial growth factor [192]
EGFR epidermal growth factor receptor, ENaC epithelial sodium channel,
PAR protease-activated receptor, TIMP tissue inhibitor of metalloproteinase
Table 2 Indirect targets of NE-dependent regulation and cognate
signaling pathways
Regulatory target Modulation by NE Signaling pathway
β-defensin 2 [193] Activation Unknown
Cathepsin B [194] Activation TLR4/IRAK
CFTR [97] Inhibition Calpain
P. aeruginosa flagellin [81] Inhibition Unknown
IL-12 p40 [195] Activation PAR-2/EGFR/TLR4
IL-8 [83, 192, 196, 197] Activation TLRs/MyD88/IRAK/TRAF-6
MHC I [198] Activation Unknown
MMP-2 [194] Activation TLR4/IRAK
MUC5AC [199, 200] Activation EGFR
EGFR epidermal growth factor receptor, ERK extracellular-regulated kinase,
IRAK-1 IL-1 receptor associated kinase-1, MHC I major histocompatibility
complex I, PAR-2 protease-activated receptor-2, TLR4 Toll-like receptor 4
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P. aeruginosa, which facilitates biofilm formation [81].
Interestingly, NE-produced fragments of CXCR1 were
identified as potential contributors to epithelial activa-
tion and release of IL-8 in a Toll-like receptor 2
(TLR2)-dependent manner [82], thus creating a patho-
logical feedback loop of neutrophil recruitment, NE re-
lease, CXCR1 cleavage on epithelial cells, and further
neutrophil recruitment. Additional contributions to this
positive feedback loop come from the NE-mediated
transcriptional upregulation of IL-8 via MyD88/IRAK/
TRAF-6 [83] and direct NE-mediated processing of IL-
8 in the extracellular milieu [84]. Indeed, IL-8 is pro-
duced as a 99-amino acid precursor protein which is
proteolytically cleaved at its N-terminus before release
[85]. Once in the extracellular milieu, IL-8 can be fur-
ther processed by extracellular proteases, such as NE,
leading to different bioactive forms that vary from 77 to
69 amino acids in length, with the 72-amino acid form
being the most potent [84]. In vitro studies also suggest
that IL-8 can be ultimately degraded in an NE-
dependent manner over time [86] which could serve to
balance out the induction of IL-8 production and its
post-transcriptional activation by NE.
It is worth mentioning that although exocytosis of pri-
mary granule content can be considered a hallmark of
CF lung disease, this process is not homogeneously
expressed among all neutrophils found in the CF airway
lumen. Indeed, Makam et al. [32] proposed a subset
classification of airway neutrophils based on their sur-
face phenotype, with neutrophils initially migrating into
the lumen and expressing low CD63 (limited primary
granule exocytosis) and high CD16 expression on their
surface, followed by the acquisition of high surface
CD63 expression (high primary granule exocytosis) and
concomitant loss of surface CD16. This striking pheno-
typic and functional transition and its implications for
CF pathogenesis are discussed in more details below.
Impact of CFTR on neutrophil function
In humans, the impact of endogenous CFTR in shaping
neutrophil effector functions is unclear, due in part to
limitations in research tools. First, animal models, such
as CFTR knockout mice, ferrets, pigs, and rats, still have
not allowed researchers in the field to adequately recapitu-
late the natural history of CF lung disease as seen in
patients, and particularly the central role played by neu-
trophils. Second, the CFTR protein is generally expressed
at low levels in cells, which, combined with the paucity of
reliable anti-CFTR antibodies, has made it difficult to
establish the presence of significant CFTR expression in
human neutrophils and how it may impact their function
[87–89].
To date, several lines of evidence support the notion
that neutrophil effector functions are not intrinsically
controlled by CFTR mutations. To begin with, the fact
that CFTR knockout animal models do not recapitulate
neutrophilic lung inflammation as seen in CF patients it-
self suggests that neutrophil dysfunction in CF patients
is due to one or several coinciding mechanism(s) unique
to humans, besides CFTR deficiency [90]. Additional
support for this idea comes from a xenograft model in
which human fetal tracheal tissues were implanted in
severe combined immunodeficient mice [91]. In this
model, mouse neutrophils (with normal CFTR expres-
sion) were recruited to CF but not non-CF xenogratfs,
emphasizing the role of the CF airway microenviron-
ment in triggering neutrophil dysfunction. Consistently,
a recent study in primary airway epithelial cultures from
CF and non-CF infants showed the existence of a pro-
inflammatory imbalance at steady state and upon stimu-
lation with a viral insult in the former compared to the
latter [23]. Furthermore, restoring CFTR expression in
the airway epithelium of CF mice is sufficient to restore
normal bacterial clearance therein, which suggests a
minimal role for CFTR expression in non-epithelial cells,
at least in this model [92]. Intriguingly, selective knock-
out of CFTR in myeloid cells in another mouse strain
led to a basal inflammatory dysfunction that was further
accentuated upon infection [93], suggesting that in mice,
the impact of CFTR on myeloid cells (including but not
limited to neutrophils) may be dependent upon the
strain and conditions tested.
From a microbiological perspective, the predominance
of a handful of bacterial species in CF lungs in vivo sug-
gests that neutrophil-mediated clearance may not be
completely abolished in this setting, but rather that dis-
tinct evolutionary pressures are at play that are unlikely
to be solely driven by CFTR-dependent dysregulation of
neutrophil phagocytosis or degranulation. Indeed, a re-
cent study showed that the CF lung pathogen P. aerugi-
nosa is resistant to neutrophil-mediated extracellular
killing, a process that is CFTR-independent [94]. Fur-
thermore, if neutrophils in CF patients were intrinsic-
ally defective due to endogenous CFTR dysfunction,
one would expect evidence of chronic infection and in-
flammation in organs other than the lungs, which is
not the case.
It is also noteworthy that in COPD and non-CF bron-
chiectasis patients devoid of a hereditary CFTR defect,
massive neutrophil transmigration also occurs in the
lungs, with subsequent release of primary granules and
impaired phagocytosis reminiscent of the picture seen in
CF patients [95, 96]. This suggests that a primary defect
in CFTR expression is not the root cause of neutrophilic
inflammation in these disease contexts. It remains pos-
sible, however, that CFTR expression may be intrinsically
normal in these patients, only to be downregulated post-
translationally due to high extracellular activity of NE,
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thus affecting neutrophil fate [97]. In CF patients,
chronic disease may lead to similar adaptive changes in
blood neutrophils. This could account, for example, for
the observed dysfunction of Rab27a in blood neutrophils
from adult CF patients, a key protein involved in ter-
tiary and secondary granule exocytosis, coupled with
the finding that significant improvement in Rab27a
function in these neutrophils can be brought upon by
ex vivo treatment with the CFTR potentiator ivacaftor
[98]. Proving the existence of an intrinsic defect in neu-
trophils in CF patients would ultimately require well-
controlled data in infants, prior to the advent of
chronic disease, a feat that has not been achieved so
far. These and other novel approaches and experimen-
tal designs will be necessary to further elucidate the eti-
ology of the abnormal neutrophil effector functions
that are manifest in CF lungs.
Immunomodulatory role of neutrophils
Since the early 1960s, significant heterogeneity among
circulating and tissue neutrophils has been recognized,
and this notion has gained further traction recently as
evidence of divergent immunomodulatory functions by
neutrophil subsets are emerging in different pathological
contexts [99]. One critical example lies in tumor micro-
environments, where neutrophils can display a strong
immunosuppressive phenotype, promoting tumor sur-
vival [100, 101]. As immunomodulatory cells, neutro-
phils modulate not only their own kin but also a variety
of other immune and structural cells. To do so, neutro-
phils use a variety of chemokines and cytokines that
regulate other cells acutely and have the potential to in-
duce chronic signaling loops that shape the long-term
immune response [102, 103].
In CF, the lumen of the lung is brimming with neutro-
phils, while it is conspicuously devoid of T cells. The en-
zyme arginase-1 can be released by neutrophils, as well
as M2-polarized macrophages and dendritic cells, lead-
ing to depletion of extracellular arginine, which in turn
can inhibit T cell activity. Arginase-dependent T cell in-
hibition is common in tumor microenvironments [104]
and upon infection with certain viruses [105]. In CF
lungs, arginase-1 is released by neutrophils, making the
airway lumen a highly inhibitory milieu for T cells [106].
In addition to the strong inhibitory role played by
neutrophil-derived arginase-1, neutrophil-derived elas-
tase can also cleave multiple critical T cell coreceptors,
therefore blocking T cell activation (see references [107]
and [108], and Table 1). Furthermore, programmed
death ligand 1 (PD-L1), a known inhibitor of T cell func-
tion in a variety of pathologies and a major target for
immunotherapy [109], was also found to be expressed in
human airway neutrophils at higher levels than on their
blood counterparts (in both CF and healthy subjects),
but with a characteristic bimodal expression in CF. In
addition, soluble PD-L1 was also detected in CF, but not
healthy, airway fluid [106]. The precise role of cell-
associated and soluble PD-L1 on T cell modulation in
CF remains to be fully explored.
Interestingly, the impact of CF airway neutrophils on T
cell function may not be solely inhibitory, since these cells
were shown to increase expression of the T-activatory sur-
face receptors major histocompatibility complex II, co-
activator CD80, and prostaglandin D2 receptor CD294,
further underlining their plasticity [69]. Expression of
major histocompatibility complex II and CD80 is conven-
tionally thought to be the prerogative of professional
antigen-presenting cells, such as dendritic cells and mac-
rophages, while CD294 is a marker for Th2-polarized im-
mune cells in the context of allergy and hypersensitivity
reactions [110]. The exact role of these T-activatory
proteins on the surface of CF airway neutrophils has
yet to be determined, although one can speculate a pos-
sible role in skewing T cell responses that may occur in
spite of arginase-1 and NE-dependent inhibition. In-
deed, it has been observed that CD4+ T cells in CF
mouse models [111] and human CF airway samples and
tissues [112–115] are skewed toward pro-inflammatory
Th2/Th17 responses, while inhibitory T-regulatory
function is inhibited.
Positive regulation of T cells by neutrophils was also
suggested in early-stage human non-small cell lung can-
cer [116], in which tumor-associated neutrophils ex-
pressing typical antigen-presenting cell markers were
able to induce T cell activation ex vivo. A recent study
has also shown the importance of neutrophils in pro-
moting a protective Th17 T cell response upon vaccin-
ation against tuberculosis [117]. Since Th17 cells and
their product IL-17 create a positive feedback loop for
neutrophil recruitment by tissues [118], neutrophil/T cell
interplay may be critical to pathogenesis in CF and other
relevant diseases. Rheumatoid arthritis (RA) is another
example of a chronic disease in which neutrophils re-
cruited from blood to the synovium dominate signaling
loops to induce a skewed immune response [119].
Metabolic licensing of neutrophils
The CF lung lumen is a very peculiar microenviron-
ment in terms of oxygen, and metabolite content. The
normal lung lumen is oxygen-rich due to constant
breathing activity. However, in diseased areas within
the CF lung lumen, neutrophil clusters, bacterial and/or
fungal colonies, and inspissated extracellular scaffolds
of mucus, DNA, and actin can lead to profound oxygen
depletion. Local hypoxia can in turn promote inflam-
mation through the release of DAMPs from host
epithelial cells [35, 120, 121]. Furthermore, the CF lung
environment has a distinct metabolite composition,
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presumably as a consequence of both CFTR dysfunction
and of the chronic presence of neutrophils and microbiota
in the lumen. First, it has been suggested that CFTR, al-
though functioning primarily as a chloride and bicarbon-
ate channel [122], can also enable transmembrane flux of
the redox intermediates glutathione (GSH) and thiocyan-
ate [123–125]. CFTR is also indirectly involved in the con-
trol of neutral amino acid transport across the epithelium
[126]. In addition, the CF lung lumen was shown to con-
tain abnormal levels of nucleotides [127], glucose, and
peptides [128].
The composition of the CF airway milieu drives adap-
tations in neutrophils, and in turn, these adaptations in-
fluence this pathological microenvironment. A telling
example is that of the redox imbalance that constitutes a
hallmark of CF. Local and systemic accumulation of oxi-
dants are believed to impact CF blood neutrophils,
which display lower intracellular GSH levels [69]. Mean-
while, reactive oxygen species produced by neutrophils
including hypochlorous acid (bleach), a byproduct of the
enzyme MPO exocytosed from primary granules at the
same time as NE, can quickly and profoundly oxidize
the lung microenvironment [129]. Finally, neutrophils
can contribute to extracellular GSH catabolism, by ex-
pressing at their surface the GSH-metabolizing enzyme
gamma-glutamyltransferase [130]. Another example is
that of arginine, which neutrophils can deplete from the
CF airway lumen by releasing arginase-1 [131] from
their granules [132]. Consequently, low availability of ar-
ginine results in decreased nitric oxide production [133]
and high levels of arginine degradation products orni-
thine and polyamines [134].
From an intracellular signaling standpoint, compara-
tive studies conducted in blood and airway neutrophils
collected from CF patients in vivo showed that these do
not differ with regard to their levels of active, phosphor-
ylated forms of the critical intermediate kinases Akt, c-
Jun-related kinase, p38 mitogen-activated protein kinase,
and p44/42 extracellular-regulated kinase or of the pro-
inflammatory transcription factors, nuclear factor κB
p65, and signal transducer and activator of transcription
5 [69]. However, CF airway neutrophils had increased
levels of phosphorylated forms of effector proteins in the
mammalian target of rapamycin pathway, a major ana-
bolic switch. These included phosphorylated S6 riboso-
mal protein [69], eukaryotic initiation factor 4E, and 4E-
binding protein 1 [32]. Additionally, levels of the phos-
phorylated cyclic AMP-response element binding pro-
tein, as well as its upstream sensors, CD114 and
receptor for advanced glycation endproducts, and down-
stream targets, CD39 and CXCR4, which function to-
gether as another anabolic switch in cells, were found to
be increased in CF airway neutrophils [32]. In aggregate,
these results suggest that CF airway neutrophils are
licensed by the microenvironment to become anabolic,
i.e., to use resources at their disposal to survive and ex-
pand their functions.
Insights gained from the analysis of intracellular
phosphorylation cascades in CF airway neutrophils
were confirmed by analysis of nutrient transporter ex-
pression. Compared to their blood counterparts, CF
airway neutrophils as a whole displayed high ex-
pression of the inorganic phosphate transporter PiT1
(necessary for ATP synthesis) and of the glucose trans-
porter Glut1, coinciding with increased glucose uptake
[135]. Subset analysis of CF airway neutrophils showed
that the degranulation of primary granules typical of
the A2 subset was associated with higher expression of
Glut1 and PiT1, and of the other inorganic phosphate
transporter PiT2. Expression of CD98, a shared sub-
unit of multiple amino acid transporters, did not differ
in CF airway compared to blood neutrophils [32], but
that of ASCT2, a neutral amino acid transporter,
was highly upregulated in the A2 subset [135]. It is
likely that this metabolic surge leads to de novo
transcription and protein production in CF airway
neutrophils, since neutrophils recruited to other
pathological environments, e.g., the synovium of RA
patients, have shown an ability to increase mRNA
output [49, 136, 137].
The combined massive and sustained recruitment of
neutrophils from blood into CF lungs (presumably lead-
ing to an increased neutrophil production in the BM),
and increased metabolic activity of these neutrophils
once they have reached the CF airway lumen are ex-
pected to impact lung tissue function and systemic me-
tabolism in patients. Indeed, the severity of CF lung
inflammation has been correlated not only to a de-
creased lung function [138] but also to decreased body
mass index [61], decreased heart function [139], and car-
diovascular complications [140]. Generally, the establish-
ment of a complex microenvironment involving not only
the chronic and massive presence of neutrophils but also
large populations of bacteria (and/or fungi) in the airway
lumen may increase the metabolic share taken by the
lung, at the expense of other organs [141].
The relationship between inflammation, high cellu-
lar turnover, and increased systemic energy expend-
iture is not confined to CF, but rather is a common
feature of an array of chronic human diseases. For ex-
ample, high body mass index at late cancer stages
predicts a higher survival rate [142]. Understanding
the mechanism underlying the anabolic switch in CF
airway neutrophils and the interplay between the dif-
ferent actors within the CF lung microenvironment
could help identify treatments impacting not only
lung disease but also the overall metabolic balance in
patients.
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The CF airway microenvironment
The existence of discrete microenvironments within the
human body is not a new concept. This concept is exem-
plified by the gut mucosa, featuring fine-tuned interplay
between the resident flora in the lumen and the immune
cells in the lamina propria, with the epithelium as an
interface. While the gut mucosa represents a normal
microenvironment, it can also become imbalanced in the
context of inflammatory bowel disease. Other pathological
conditions can lead to the formation of microenviron-
ments in organs that do not normally harbor a significant,
stable population of inflammatory cells and/or associated
microbiota. CF, RA, and several forms of cancer serve as
examples of such pathological microenvironments featur-
ing a dominant neutrophilic component.
A key element in the formation of pathological microen-
vironments is the establishment of tolerance and cooper-
ation between the different players, enabling an acute
process to become chronicized. For instance, inflamma-
tory bowel disease is characterized by a massive neutrophil
infiltration in the gut [143, 144] and as the disease pro-
gresses, neutrophils orchestrate with the gut epithelium
the advent of a chronic state. Consequently, adaptive re-
sponses are dampened [145], and neutrophils and bacteria
coexist in concentric luminal structures termed “casts”
[146]. A similar scenario unfolds in CF, where neutrophils
interact with the airway epithelium and opportunistic bac-
teria such as P. aeruginosa and S. aureus to establish
multi-decade colonies, featuring minimal involvement of
adaptive immune cells, and structures in the lumen where
bacteria and neutrophils coexist [147].
Recent studies suggest that the formation of patho-
logical microenvironments featuring substantial relocation
of hematopoietic cells within a peripheral organ can
impact other distal organs besides the BM, where
hematopoiesis takes place. For example, Masri et al. [148]
have shown that establishment of a lung tumor mass can
lead to re-tuning of the liver circadian clock and repro-
gramming of its nutrient output in order to support the
metabolic requirements of the remote lung tumor.
Whether the establishment of a pathological microenvir-
onment in the CF lung does not only involve complex
local coordination but also impact other organs in the
body (notably the liver and gut, in order to respond to its
metabolic demands) remains to be established. Taken to-
gether, evidence from in vivo and in vitro studies suggest
that, at a minimum, the airway epithelium, recruited neu-
trophils, and bacteria present in the CF microenvironment
coevolve over time to enable a somewhat peaceful, albeit
tissue-damaging, coexistence, as illustrated in Fig. 2.
Treatment opportunities
The development of drugs aimed to treat CF has mainly
focused on fluidifying secretions, regulating microbial
burden and, more recently, rescuing mutant CFTR func-
tion. The latter approach has paid substantial dividends
with the drug ivacaftor for CFTR gating mutants such as
G551D. However, the downside of this approach is that
Fig. 2 Development and evolution of a pathological microenvironment in CF airways. From birth to adulthood, CF patients undergo stepwise
changes to their airway microenvironment. In the first phase (left), neutrophil start to accumulate in the lumen in response to cues from the
underlying epithelium, prior to the advent of chronic infection. The second phase (middle) features the stable coexistence of an even more
substantial population of luminal neutrophils with planktonic bacteria (in red, drawn with flagellum to exemplify P. aeruginosa, the gram-negative
pathogen most commonly found in CF patients). In the third phase (right), bacteria switch to a resistant and generally avirulent and auxotrophic
mode of existence, encased in an extracellular molecular scaffold (mucoid or biofilm forms, in yellow), with a very large population of neutrophils
organized as a cast around them. Shown under the epithelium are the critical environmental conditions that change during the formation of this
pathological microenvironment, including the degree of airway obstruction (increasing), and luminal levels of oxygen (decreasing as neutrophil
activate their reactive oxygen species burst) and lactic acid (increasing with neutrophil glycolytic activity), pH (decreasing as lactic acid accumu-
lates), as well the burden of free NE and DNA (both correlated positively with neutrophil presence)
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it is mutation-specific and benefits only a small percent-
age of CF patients [149]. So far, only little attention has
been paid to the regulation of neutrophil function, since
the long-held view has been that these cells die quickly
upon migration to CF lungs. Data discussed in this re-
view clearly contradict this view and open new avenues
for neutrophil-focused therapies in CF.
Conventional anti-inflammatory drugs, including ibu-
profen and prednisone, have shown beneficial, albeit
marginal, effects by slowing down CF disease progres-
sion [150, 151]. However, prednisone treatment of CF
patients is not common due to important side effects on
growth [152]. More recent efforts focused on drugs de-
signed to inhibit neutrophil recruitment to the CF lung,
such as BIIL 284, a LTB4 receptor antagonist [153], and
SB 656933, a CXCR2 antagonist [154]. Both drugs led to
an increase in inflammatory signaling (increased fre-
quency of exacerbations for the former, and increased
circulating inflammatory mediators for the latter), sug-
gesting that inhibiting neutrophil recruitment to the CF
lung may prove detrimental for patients [155]. In
addition to inhibiting neutrophil recruitment into the
lung lumen, BIIL 284 was also found to promote apop-
tosis of neutrophils that had transmigrated [156].
Arguably, focus should now be put on the development
of drugs directed toward regulating neutrophil function
or aiming to orchestrate their chemotaxis to the lung to
attain normal homeostatic levels, rather than blocking
their recruitment, which could lead to detrimental, sub-
normal levels of these cells within the lung lumen.
Since NE activity is elevated in CF patients and corre-
lates with disease progression, development of NE inhibi-
tors has been of prime interest [157, 158]. Unfortunately,
due to the high amount of NE present in CF airways, its
broad range of substrates, and its compartmentalization
as both a free-floating, mucus-associated, and membrane-
bound enzyme [55], the design of inhibitors and modes of
administration have to be significantly improved to attain
therapeutic efficacy [159]. In a recently introduced ap-
proach, Forde et al. [160] leveraged NE activity in diseased
airways to process a synthetic pro-drug, giving rise to a
fully active anti-infectious small peptide. A similar
approach could be applied to design NE-activated immu-
nomodulatory drugs. Examples of relevant immuno-
modulatory drugs includes agents able to (i) target the
organizing stage of neutrophil swarming preceding their
transepithelial migration, which may reduce, as opposed
to fully abrogate their recruitment to the lung; (ii)
Fig. 3 Neutrophils as protagonists among contributors to CF airway disease. Neutrophils (center) establish metabolic and signaling ties with lung
epithelial cells (bottom right) and resident planktonic and mucoid/biofilm bacteria (bottom left), while exerting primarily inhibitory control over
other immune cells, including T cells and macrophages (top). The result of these complex relationships is the formation of a relatively stable
pathological microenvironment within CF airways
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manipulate the metabolism and/or functional fate of neu-
trophils, to promote phagocytosis while reducing NETosis
and degranulation/reprogramming; and (iii) regulate the
lifespan of airway neutrophils or interfere with other
factors enabling the establishment of a pathological,
neutrophil-driven microenvironment in CF lungs.
Conclusions
In the last decade, monumental progress has been made
to understand the processes characterizing the peculiar
situation of CF lung disease. Despite extensive work,
there is much more to be explored regarding neutrophil
functions and plasticity, and their ability to occupy a
central place in the development of a pathological
microenvironment in CF lungs (Fig. 3).
Neutrophils currently enjoy renewed interest from
basic and clinical researchers, as emerging evidence sup-
ports the idea that mechanisms of metabolic and func-
tional plasticity described here are not confined to CF.
Therefore, a better understanding of molecular mecha-
nisms underlying neutrophil plasticity and neutrophil-
epithelium-microbial partnership should help identify
novel targets for treatments aiming to normalize patho-
logical microenvironment development in CF, and simi-
lar neutrophil-driven diseases such as COPD, RA, and
certain forms of cancer. Expanding our knowledge in
terms of crosstalk between metabolic switching, inter-
connecting pathways and effector functions in neutro-
phils will be of high value for innumerable reasons. To
close this review, we invite readers to consult Fig. 4,
which lists several of the open questions pertaining to
neutrophil plasticity and function that will need to be
addressed in the near future.
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